
Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD)
WebsitePrice
Market cap
Next catalystExpected Q4 2026Zoldonrasib plus cetuximab and FOLFOX or FOLFIRI — RASonate 312 · Trial initiationCompany source ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Partner / License out
Approved / commercial
PreINDP1P2P3FilingApproved